Abstract
IMPORTANCE OF THE FIELD
A dramatic increase in infections caused by methicillin-resistant Staphylococcus aureus (MRSA) has been observed, in part as a result of the epidemic of community-associated MRSA skin and skin-structure infections (SSSIs). Simultaneously, decreasing sensitivities of S. aureus to vancomycin have been reported and invasive infections caused by these strains have been associated with worse clinical outcomes. Clearly, new agents active against MRSA are needed. Ceftaroline is a new cephalosporin active against MRSA and many Gram-negative bacteria, though it is not active against Pseudomonas spp. and extended spectrum beta-lactamase producers (ESBL).
AREAS COVERED IN THIS REVIEW
In this review we focus on the properties of ceftaroline such as in vitro activity, the pharmacokinetic and pharmacodynamic characteristics, and its efficacy and safety observed in the clinical trials of patients with SSSI. Finally, we provide an overview of the possible future role of ceftaroline and other compounds in development for the treatment of SSSIs. The literature search was based on PubMed articles plus review of the abstracts presented in the most important international conferences in the field.
WHAT THE READER WILL GAIN
The reader will gain clear concepts to understand the value that ceftaroline might have in the treatment of SSSIs, including those caused by MRSA.
TAKE HOME MESSAGE
Ceftaroline has shown bactericidal activity against common pathogens associated with SSSIs including MRSA, noninferiority in clinical trials of patients with complicated SSSI (cSSSI), and a favorable safety profile.
TY - JOUR
T1 - Ceftaroline for complicated skin and skin-structure infections.
AU - Nannini,Esteban C,
AU - Stryjewski,Martin E,
AU - Corey,G Ralph,
PY - 2010/4/21/entrez
PY - 2010/4/21/pubmed
PY - 2010/7/10/medline
SP - 1197
EP - 206
JF - Expert opinion on pharmacotherapy
JO - Expert Opin Pharmacother
VL - 11
IS - 7
N2 - IMPORTANCE OF THE FIELD: A dramatic increase in infections caused by methicillin-resistant Staphylococcus aureus (MRSA) has been observed, in part as a result of the epidemic of community-associated MRSA skin and skin-structure infections (SSSIs). Simultaneously, decreasing sensitivities of S. aureus to vancomycin have been reported and invasive infections caused by these strains have been associated with worse clinical outcomes. Clearly, new agents active against MRSA are needed. Ceftaroline is a new cephalosporin active against MRSA and many Gram-negative bacteria, though it is not active against Pseudomonas spp. and extended spectrum beta-lactamase producers (ESBL). AREAS COVERED IN THIS REVIEW: In this review we focus on the properties of ceftaroline such as in vitro activity, the pharmacokinetic and pharmacodynamic characteristics, and its efficacy and safety observed in the clinical trials of patients with SSSI. Finally, we provide an overview of the possible future role of ceftaroline and other compounds in development for the treatment of SSSIs. The literature search was based on PubMed articles plus review of the abstracts presented in the most important international conferences in the field. WHAT THE READER WILL GAIN: The reader will gain clear concepts to understand the value that ceftaroline might have in the treatment of SSSIs, including those caused by MRSA. TAKE HOME MESSAGE: Ceftaroline has shown bactericidal activity against common pathogens associated with SSSIs including MRSA, noninferiority in clinical trials of patients with complicated SSSI (cSSSI), and a favorable safety profile.
SN - 1744-7666
UR - https://www.unboundmedicine.com/medline/citation/20402556/Ceftaroline_for_complicated_skin_and_skin_structure_infections_
L2 - https://www.tandfonline.com/doi/full/10.1517/14656561003777026
DB - PRIME
DP - Unbound Medicine
ER -
